ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: Lancet
Author(s): Richard P Whitlock, PJ Devereaux, Kevin H Teoh, Andre Lamy, Jessica Vincent, Janice Pogue, Domenico Paparella, Daniel I Sessler, Ganesan Karthikeyan, Juan Carlos Villar, Yunxia Zuo, Álvaro Avezum, Mackenzie Quantz, Georgios I Tagarakis, Pallav J Shah, Seyed Hesameddin Abbasi, Hong Zheng, Shirley Pettit, Susan Chrolavicius, and Salim Yusuf for the SIRS Investigators


In this RCT, patients at increased risk for cardiac surgery requiring CPB were assigned to steroids at the time of anesthetic induction and again at the time of CPB induction or no steroids.  Primary outcomes were 30-day mortality and major morbidity.  Steriods had no effect on the primary outcomes.  There was no evidence that steroids increased the risk of other complications, particularly infection, surgical site infection, and delirium.

Source: Journal of the American College of Cardiology
Author(s): Robert H. Habib; Kamellia R. Dimitrova; Sanaa A. Badour; Maroun B. Yammine; Abdul-Karim M. El-Hage-Sleiman; Darryl M. Hoffman; Charles M. Geller; Thomas A. Schwann; Robert F. Tranbaugh

The investigators of this study compared survival of bare metal stent percutaneous coronary intervention (BMS-PCI) versus drug-eluting stent PCI (DES-PCI) versus single artery CABG (SA-CABG) versus multiarterial CABG (MA-CABG) in patients with multivessel coronary artery disease. They used propensity-matching and Cox regression techniques in more than 8000 patients from 1 institution. The authors found that survival after DES-PCI was higher than after BMS-PCI. Long-term survival after DES-PCI was similar to SA-CABG. However, when compared to MA-CABG, the DES-PCI group showed worse survival at 5 years (86.3% versus 95.6%) and at 9 years (82.8% versus 89.8%; HR 0.45, p<0.001). The authors conclude that MA-CABG should be adopted as the optimal therapy for multivessel coronary heart disease.

Source: Institute for Surgery and Innovation
Author(s): Tom D'Amico

This is a fabulous grand round presentation from Tom D'Amico documenting the history and the future of thoracoscopic lobectomy. A Must see for thoracic surgeons 

Source: Annals of Thoracic Surgery
Author(s): Gorav Ailawadi, MD, Damien J. LaPar, MD, MS∗†, Alan M. Speir, MD†, Ravi K. Ghanta, MD†, Leora T. Yarboro, MD†, Ivan K. Crosby, MD†, D. Scott Lim, MD, Mohammed A. Quader, MD†, Jeffrey B. Rich, MD†

The authors conducted a propensity-matched analysis of outcomes and costs associated with TAVR vs. SAVR procedures in patients considered either intermediate risk (STS PROM 4-8%) or high risk (STS PROM >8%) within the Commonwealth of Virginia.  Although the incidence of major morbidity was higher and the length of stay was longer with SAVR, the mortality was higher for TAVR (10% vs. 6%, p<0.047).  Importantly, the median total costs of the implant hospitalization were more than double for the TAVR group in comparison to the SAVR group ($69,921 vs. $33,598).  Not surprisingly, the dominant cost driver for TAVR was the cost of the device, which accounted for 40% of the cost of the implant hospitalization.

 

Source: Journal of Thoracic Oncology
Author(s): Puri, Varun; Crabtree, Traves D.; Bell, Jennifer M.; Broderick, Stephen R; Morgensztern, Daniel; Colditz, Graham A.; Kreisel, Daniel; Krupnick, A. Sasha; Patterson, G. Alexander; Meyers, Bryan F.; Patel, Aalok; Robinson, Clifford G.

A large retrospective study comparing 117618 patients from the National Cancer Database with Stage I NSCLC. 111731 received surgery, 5887 received SBRT. In a propensity managed comparison, those undergoing surgery had increased overall survival.

Source: Journal of Thoracic and Cardiovascular Surgery
Author(s): G Hossein Almassi, MD, Brendan M. Carr, MD, Muath Bishawi, MD, MPH, A. Laurie Shroyer, PhD, Jacquelyn A. Quin, MD, Brack Hattler, MD, Todd H. Wagner, PhD, Joseph F. Collins, ScD, Pasala Ravichandran, MB, FRCS, Joseph C. Cleveland, MD, Frederick L. Grover, MD, Faisal G. Bakaeen, MD for the VA #517 Randomized On/Off Bypass (ROOBY) Study Group

This sub-study of the Randomized On/Off Bypass (ROOBY) trial compared clinical outcomes and 1-year graft patency between CABG cases where residents vs. attending surgeons were the primary operator. Graft patency rates were similar between resident- vs. attending-completed distal anastomoses for on-pump (83.0% vs. 82.4%) and off-pump (77.2% vs. 76.6%) procedures. 

Source: Eur J Cardiothorac Surg
Author(s): Grant SW, Hickey GL, Ludman P, Moat N, Cunningham D, de Belder M, Blackman DJ, Hildick-Smith D, Uppal R, Kendall S, Bridgewater B

This study describes activity and outcomes for both standard aortic valve implantation and transcatheter aortic valve implantation (TAVI) in England and Wales in the TAVI era. The study demonstrates that both standard aortic valve implantation and TAVI acitivity have increased since TAVI was first performed in the United Kingdom. The proportion of all aortic valve implantations performed by TAVI has increased from 0.8% in 2007 to 10.9% in 2012. Procedural outcomes have improved for both standard AVR and TAVI over time.

Source: Interact CardioVasc Thorac Surg
Author(s): Satoshi Yamashiro, Ryoko Arakaki, Yuya Kise, Hitoshi Inafuku, and Yukio Kuniyoshi

Authors report on visceral malperfusion in a series of 121 patients with acute type A aortic dissection. They postulate that in case of severe visceral ischaemia, abdominal surgery should be performed first to avoid irreversible ischaemic damage caused by circulatory arrest required for aortic repair. 

Source: Eur J Cardiothorac Surg
Author(s): Arudo Hiraoka, Jeffrey E. Cohen, Yasuhiro Shudo, John W. MacArthur, Jr, Jessica L. Howard, Alexander S. Fairman, Pavan Atluri, James N. Kirkpatrick, and Y. Joseph Woo

The paper evaluates de novo development of aortic insufficiency (AI) following implantation of continuous flow left ventricular assist (84 HeartMate II, 13 HeartWare, 2 VentrAssist). Preoperatively, 17 patients had mild AI, which did not change later. Fourty-three of the other 82 patients developed new AI, with no influence on survival.  Rate of freedom from de novo AI at 1 year after VAD implantation was 35.9%. Smaller body surface area, larger aortic root diameter and higher pulmonary artery systolic pressure were identified as the independent preoperative risk factors. 

Source: Eur J Cardiothorac Surg
Author(s): Ei Miyamoto, Fengshi Chen, Akihiro Aoyama, Masaaki Sato, Tetsu Yamada, and Hiroshi Date

This single-center study analyses outcomes of living-donor lobar lung transplantations. Eight out of 38 patients who survived more than three months developed chronic lung allograft dysfunction (CLAD). Six of these eight patients had undergone bilateral transplantation. Unilateral CLAD was observed in three and bilateral CLAD developed in the other three patients. 

Pages